Literature DB >> 32022598

TSH RECEPTOR ANTIBODIES: RELEVANCE & UTILITY.

George J Kahaly, Tanja Diana, Paul D Olivo.   

Abstract

Objective: Antibodies (Abs) to the thyrotropin (TSH) receptor (TSH-R) play an important role in the pathogenesis of autoimmune thyroid disease (AITD). We define the complex terminology that has arisen to describe TSH-R-Abs, review the mechanisms of action of the various types of TSH-R-Abs, and discuss significant advances that have been made in the development of clinically useful TSH-RAb assays.
Methods: Literature review and discussion.
Results: TSH-R-Abs may mimic or block the action of TSH or be functionally neutral. Stimulating TSH-R-Abs are specific biomarkers for Graves disease (GD) and responsible for many of its clinical manifestations. TSH-R-Abs may also be found in patients with Hashimoto thyroiditis in whom they may contribute to the hypothyroidism of the disease. Measurement of TSH-R-Abs in general, and functional Abs in particular, is recommended for the rapid diagnosis of GD, differential diagnosis and management of patients with AITD, especially during pregnancy, and in AITD patients with extrathyroidal manifestations such as orbitopathy. Measurement of TSH-R-Abs can be done with either immunoassays that detect specific binding of Abs to the TSH-R or cell-based bioassays that also provide information on their functional activity and potency. Application of molecular cloning techniques has led to significant advances in methodology that have enabled the development of clinically useful bioassays. When ordering TSH-R-Ab, clinicians should be aware of the different tests available and how to interpret results based on which assay is performed. The availability of an international standard and continued improvement in bioassays will help promote their routine performance by clinical laboratories and provide the most clinically useful TSH-R-Ab results.
Conclusion: Measurement of TSH-R-Abs in general, and functional (especially stimulating) Abs in particular, is recommended for the rapid diagnosis, differential diagnosis, and management of patients with Graves hyperthyroidism, related thyroid eye disease, during pregnancy, as well as in Hashimoto thyroiditis patients with extra-thyroidal manifestations and/or thyroid-binding inhibiting immunoglobulin positivity. Abbreviations: Ab = antibody; AITD = autoimmune thyroid disease; ATD = antithyroid drug; cAMP = cyclic adenosine 3',5'-monophosphate; ELISA = enzyme-linked immunosorbent assay; GD = Graves disease; GO = Graves orbitopathy; HT = Hashimoto thyroiditis; MAb = monoclonal antibody; TBAb = thyrotropin receptor blocking antibody; TBII = thyroid-binding inhibiting immunoglobulin; TSAb = thyrotropin receptor-stimulating antibody; TSB-Ab or TRBAb = thyrotropin receptor-stimulating blocking antibody; TSH = thyrotropin; TSH-R = thyrotropin receptor.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32022598     DOI: 10.4158/EP-2019-0363

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  24 in total

1.  2021 European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction.

Authors:  Tomasz Bednarczuk; Thomas H Brix; Wolfgang Schima; Georg Zettinig; George J Kahaly
Journal:  Eur Thyroid J       Date:  2021-06-16

2.  Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays.

Authors:  Christine C Krieger; George J Kahaly; Asma Azam; Joanna Klubo-Gwiezdzinska; Susanne Neumann; Marvin C Gershengorn
Journal:  Thyroid       Date:  2021-11-29       Impact factor: 6.568

Review 3.  Advances in the differential diagnosis of transient hyperthyroidism in pregnancy and Graves' disease.

Authors:  Nian Guo; Meng Xue; Zhen Liang
Journal:  Arch Gynecol Obstet       Date:  2022-09-16       Impact factor: 2.493

Review 4.  2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease.

Authors:  Thanh D Hoang; Derek J Stocker; Eva L Chou; Henry B Burch
Journal:  Endocrinol Metab Clin North Am       Date:  2022-05-11       Impact factor: 4.748

Review 5.  Assessment and treatment of thyroid disorders in pregnancy and the postpartum period.

Authors:  Sun Y Lee; Elizabeth N Pearce
Journal:  Nat Rev Endocrinol       Date:  2022-01-04       Impact factor: 47.564

6.  Development of Low-Molecular-Weight Allosteric Agonist of Thyroid-Stimulating Hormone Receptor with Thyroidogenic Activity.

Authors:  A A Bakhtyukov; K V Derkach; E A Fokina; V N Sorokoumov; I O Zakharova; L V Bayunova; A O Shpakov
Journal:  Dokl Biochem Biophys       Date:  2022-05-10       Impact factor: 0.834

7.  A Novel Long-Term Graves' Disease Animal Model Confirmed by Functional Thyrotropin Receptor Antibodies.

Authors:  Tanja Diana; Hans-Peter Holthoff; Julia Fassbender; Christian Wüster; Michael Kanitz; George J Kahaly; Martin Ungerer
Journal:  Eur Thyroid J       Date:  2020-07-23

8.  Novel Approaches for Immunosuppression in Graves' Hyperthyroidism and Associated Orbitopathy.

Authors:  Alan Chun Hong Lee; George J Kahaly
Journal:  Eur Thyroid J       Date:  2020-08-10

Review 9.  Testing, Monitoring, and Treatment of Thyroid Dysfunction in Pregnancy.

Authors:  Sun Y Lee; Elizabeth N Pearce
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

10.  Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy.

Authors:  G J Kahaly; S Ignjatović; M Sarić Matutinović; T Diana; B Nedeljković Beleslin; J Ćirić; M Žarković
Journal:  J Endocrinol Invest       Date:  2021-07-29       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.